Hepatocellular carcinoma (HCC) · line 2 · Ramucirumab (HCC, 2L high AFP)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-RAMUCIRUMAB-HCC |
| ID | IND-HCC-SYSTEMIC-2L-RAMUCIRUMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-HCC |
| Sources | SRC-NCCN-HCC-2025 SRC-REACH2-ZHU-2019 |
Notes
REACH-2 (PMID 30922890) established AFP≥400 as the first validated biomarker for HCC 2L selection. AFP is routinely measured in HCC — no additional testing burden. Note: BIO-AFP entity may not exist in KB — verify before deploying; use AFP as a free-text condition in the algorithm if BIO-AFP is absent.
Used By
Algorithms
ALGO-HCC-SYSTEMIC-2L- ALGO-HCC-SYSTEMIC-2L